Best Stocks Under $5 Right Now It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. This page lists cheap stocks that have a share price of $5.00 (5 dollars) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts. OverviewStocks Under $0.05Stocks Under $0.10Stocks Under $0.25Stocks Under $0.50Stocks Under $1Stocks Under $2Stocks Under $3Stocks Under $5Stocks Under $10Stocks Under $20Stocks Under $30Stocks Under $50Stocks On Sale 1. Ur Energy NYSEAMERICAN:URG$1.34 +0.05 (+3.46%) As of 10:21 AM Eastern This is a fair market value price provided by Massive. Learn more.Ur-Energy Inc engages in the acquisition, exploration, development, and operation of uranium mineral properties. The company holds interests in 12 projects located in the United States. More about Ur EnergyMarket Capitalization$534.41 millionConsensus RatingBuyConsensus Price Target$2.57 (+90.8% Upside)Volume1.60 million sharesAverage Volume10.01 million sharesToday's Range$1.29▼$1.36 Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. 2. Curaleaf OTCMKTS:CURLF$3.64 0.00 (0.00%) As of 06/4/2026Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. More about CuraleafMarket Capitalization$2.54 billionConsensus RatingBuyVolume1.32 million sharesAverage Volume1.24 million sharesToday's Range$3.33▼$3.8350-Day Range$3.64▼$11.973. iBio NASDAQ:IBIO$1.60 +0.02 (+0.94%) As of 10:20 AM Eastern This is a fair market value price provided by Massive. Learn more.iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. More about iBioMarket Capitalization$80.73 millionConsensus RatingBuyConsensus Price Target$5.00 (+211.5% Upside)Volume30,400 sharesAverage Volume1.31 million sharesToday's Range$1.57▼$1.624. Inhibikase Therapeutics NASDAQ:IKT$1.92 +0.06 (+2.94%) As of 10:20 AM Eastern This is a fair market value price provided by Massive. Learn more.Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. More about Inhibikase TherapeuticsMarket Capitalization$254.16 millionConsensus RatingBuyConsensus Price Target$5.40 (+180.5% Upside)Volume48,833 sharesAverage Volume1.32 million sharesToday's Range$1.84▼$1.925. Perspective Therapeutics NYSEAMERICAN:CATX$3.10 +0.11 (+3.50%) As of 10:21 AM Eastern This is a fair market value price provided by Massive. Learn more.Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. More about Perspective TherapeuticsMarket Capitalization$352.99 millionConsensus RatingBuyConsensus Price Target$12.63 (+306.6% Upside)Volume107,591 sharesAverage Volume2.49 million sharesToday's Range$2.99▼$3.146. Inventiva NASDAQ:IVA$3.52 +0.02 (+0.43%) As of 10:21 AM Eastern This is a fair market value price provided by Massive. Learn more.Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. More about InventivaMarket Capitalization$728.44 millionConsensus RatingBuyConsensus Price Target$16.56 (+371.0% Upside)Volume127,924 sharesAverage Volume518,833 sharesToday's Range$3.44▼$3.567. Larimar Therapeutics NASDAQ:LRMR$3.54 +0.05 (+1.29%) As of 10:21 AM Eastern This is a fair market value price provided by Massive. Learn more.Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. More about Larimar TherapeuticsMarket Capitalization$369.29 millionConsensus RatingBuyConsensus Price Target$13.50 (+280.8% Upside)Volume100,178 sharesAverage Volume2.97 million sharesToday's Range$3.52▼$3.638. DiDi Global OTCMKTS:DIDIY$3.41 -0.07 (-2.01%) As of 10:00 AM EasternDiDi Global Inc operates a mobility technology platform that provides ride hailing and other services in the People's Republic of China, Brazil, Mexico, and internationally. More about DiDi GlobalMarket Capitalization$15.54 billionConsensus RatingBuyConsensus Price Target$8.60 (+152.2% Upside)Volume866,878 sharesAverage Volume7.90 million sharesToday's Range$3.36▼$3.469. Aquestive Therapeutics NASDAQ:AQST$4.43 -0.04 (-0.78%) As of 10:20 AM Eastern This is a fair market value price provided by Massive. Learn more.Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. More about Aquestive TherapeuticsMarket Capitalization$550.10 millionConsensus RatingBuyConsensus Price Target$8.50 (+91.7% Upside)Volume183,982 sharesAverage Volume3.17 million sharesToday's Range$4.36▼$4.4810. Standard Lithium NYSEAMERICAN:SLI$2.90 -0.03 (-1.02%) As of 09:59 AM EasternStandard Lithium Ltd. explores for, develops, and processes lithium brine properties in the United States. Its flagship project is the Lanxess project with area of approximately 150,000 acres located in southern Arkansas. More about Standard LithiumMarket Capitalization$711.78 millionConsensus RatingBuyConsensus Price Target$5.13 (+76.7% Upside)Volume336,507 sharesAverage Volume2.20 million sharesToday's Range$2.82▼$2.9311. Stereotaxis NYSEAMERICAN:STXS$1.62 +0.01 (+0.31%) As of 10:20 AM Eastern This is a fair market value price provided by Massive. Learn more.Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. More about StereotaxisMarket Capitalization$158.83 millionConsensus RatingBuyConsensus Price Target$3.88 (+138.5% Upside)Volume39,106 sharesAverage Volume453,833 sharesToday's Range$1.60▼$1.6512. StorageVault Canada OTCMKTS:SVAUF$3.31 0.00 (0.00%) As of 06/25/2026 01:42 PM EasternStorageVault Canada Inc owns, manages, and rents self-storage and portable storage space to individual and commercial customers in Canada. More about StorageVault CanadaConsensus RatingBuyVolume50,217 sharesAverage Volume31,037 sharesToday's Range$3.31▼$3.3150-Day Range$3.00▼$3.4152-Week Range$2.66▼$3.7813. Peraso NASDAQ:PRSO$0.80 +0.00 (+0.53%) As of 10:21 AM Eastern This is a fair market value price provided by Massive. Learn more.Peraso Inc, a fabless semiconductor company, develops, markets, and sells semiconductor devices and modules. The company's products include millimeter wavelength (mmWave) ICs, including baseband IC, various mmWave radio frequency, integrated circuits, as well as associated antenna technology; and mmWave antenna modules. More about PerasoMarket Capitalization$11.72 millionConsensus RatingBuyConsensus Price Target$3.00 (+277.4% Upside)Volume141,285 sharesAverage Volume4.75 million sharesToday's Range$0.76▼$0.7914. Adagene NASDAQ:ADAG$4.24 +0.12 (+2.82%) As of 10:20 AM Eastern This is a fair market value price provided by Massive. Learn more.Adagene Inc, a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. More about AdageneMarket Capitalization$200.93 millionConsensus RatingBuyConsensus Price Target$8.00 (+88.9% Upside)Volume2,963 sharesAverage Volume212,273 sharesToday's Range$4.06▼$4.2515. Nano-X Imaging NASDAQ:NNOX$1.18 +0.31 (+34.75%) As of 10:21 AM Eastern This is a fair market value price provided by Massive. Learn more.Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source. The company provides teleradiology services and develops artificial intelligence applications to be used in real-world medical imaging applications. More about Nano-X ImagingMarket Capitalization$81.77 millionConsensus RatingBuyConsensus Price Target$5.00 (+321.9% Upside)Volume9.06 million sharesAverage Volume1.42 million sharesToday's Range$0.77▼$1.2216. Trilogy Metals NYSEAMERICAN:TMQ$3.38 +0.04 (+1.11%) As of 10:21 AM Eastern This is a fair market value price provided by Massive. Learn more.Trilogy Metals Inc, a base metals exploration company, engages in the exploration and development of mineral properties in the United States. More about Trilogy MetalsMarket Capitalization$582.70 millionConsensus RatingBuyConsensus Price Target$7.75 (+129.5% Upside)Volume168,762 sharesAverage Volume3.68 million sharesToday's Range$3.26▼$3.4017. Opus Genetics NASDAQ:IRD$3.99 +0.27 (+7.34%) As of 10:21 AM Eastern This is a fair market value price provided by Massive. Learn more.Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. More about Opus GeneticsMarket Capitalization$329.69 millionConsensus RatingModerate BuyConsensus Price Target$10.77 (+169.7% Upside)Volume88,670 sharesAverage Volume892,887 sharesToday's Range$3.72▼$3.9818. Atai Beckley NASDAQ:ATAI$4.82 +0.25 (+5.35%) As of 10:21 AM Eastern This is a fair market value price provided by Massive. Learn more.Atai Beckley N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. More about Atai BeckleyMarket Capitalization$1.74 billionConsensus RatingModerate BuyConsensus Price Target$16.00 (+231.6% Upside)Volume1.17 million sharesAverage Volume5.20 million sharesToday's Range$4.42▼$4.7219. Verastem NASDAQ:VSTM$3.52 +0.07 (+1.88%) As of 10:21 AM Eastern This is a fair market value price provided by Massive. Learn more.Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. More about VerastemMarket Capitalization$305.52 millionConsensus RatingModerate BuyConsensus Price Target$14.60 (+315.4% Upside)Volume524,391 sharesAverage Volume2.13 million sharesToday's Range$3.44▼$3.5520. CytomX Therapeutics NASDAQ:CTMX$3.33 +0.06 (+1.93%) As of 10:21 AM Eastern This is a fair market value price provided by Massive. Learn more.CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. More about CytomX TherapeuticsMarket Capitalization$566.21 millionConsensus RatingModerate BuyConsensus Price Target$12.10 (+263.0% Upside)Volume184,659 sharesAverage Volume5.22 million sharesToday's Range$3.23▼$3.3221. Grab NASDAQ:GRAB$3.46 +0.01 (+0.14%) As of 10:21 AM Eastern This is a fair market value price provided by Massive. Learn more.Grab Holdings Limited engages in the provision of superapps in Cambodia, Indonesia, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam. More about GrabMarket Capitalization$14.20 billionP/E Ratio346.95Consensus RatingModerate BuyConsensus Price Target$6.19 (+78.6% Upside)Volume5.36 million sharesAverage Volume50.96 million shares22. Ovid Therapeutics NASDAQ:OVID$2.56 +0.14 (+5.58%) As of 10:21 AM Eastern This is a fair market value price provided by Massive. Learn more.Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. More about Ovid TherapeuticsMarket Capitalization$476.87 millionConsensus RatingModerate BuyConsensus Price Target$5.13 (+100.6% Upside)Volume179,041 sharesAverage Volume2.54 million sharesToday's Range$2.39▼$2.5323. Context Therapeutics NASDAQ:CNTX$0.58 +0.02 (+3.57%) As of 10:20 AM Eastern This is a fair market value price provided by Massive. Learn more.Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. More about Context TherapeuticsMarket Capitalization$53.29 millionConsensus RatingModerate BuyConsensus Price Target$6.17 (+963.2% Upside)Volume394,952 sharesAverage Volume1.55 million sharesToday's Range$0.56▼$0.5924. Autolus Therapeutics NASDAQ:AUTL$1.64 +0.06 (+3.46%) As of 10:20 AM Eastern This is a fair market value price provided by Massive. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. More about Autolus TherapeuticsMarket Capitalization$437.83 millionConsensus RatingModerate BuyConsensus Price Target$8.75 (+431.9% Upside)Volume111,043 sharesAverage Volume1.66 million sharesToday's Range$1.59▼$1.6725. Lexeo Therapeutics NASDAQ:LXEO$4.80 +0.10 (+2.21%) As of 10:21 AM Eastern This is a fair market value price provided by Massive. Learn more.Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. More about Lexeo TherapeuticsMarket Capitalization$376.20 millionConsensus RatingModerate BuyConsensus Price Target$18.75 (+290.3% Upside)Volume36,565 sharesAverage Volume930,810 sharesToday's Range$4.67▼$4.92 More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone Micron’s HBM Surge Could Redefine the AI Growth Story Carnival's Second Quarter: Is the Stock Still Complicated? Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal MDA Space Targets US Defense Market With $620M Acquisition Qualcomm’s $4B AI Deal Takes Aim at NVIDIA’s Software Moat Cerebras Systems, Inc: The Next Rags-to-Riches AI Story? Domino's Stock Slides to 52-Week Low as Investors Digest CEO Change Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
